Despite their remarkable anti-tumor activity, agents like the B-cell receptor (BCR) signaling inhibitors and the Bcl-2 protein inhibitor venetoclax have some limitations, which include the development of drug resistance mechanisms and the less striking efficacy observed in patients carrying biological high-risk features [as reviewed in (156)]. This evidence concerns the gene BCL2 and neoplasm.